Free Trial

Context Therapeutics (CNTX) SEC Filings & 10K Form

Context Therapeutics logo
$0.81 -0.02 (-2.01%)
As of 12:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Context Therapeutics SEC Filings

DateFilerForm TypeView
02/28/2025
3:06 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
9:02 AM
Avidity Partners Management LP (Filed by)
Context Therapeutics (Subject)
Form SCHEDULE 13G/A
02/14/2025
5:27 AM
Context Therapeutics (Subject)
Opaleye Management Inc. (Filed by)
Form SCHEDULE 13G/A
02/12/2025
4:20 PM
Context Therapeutics (Subject)
Lehr Martin A. (Filed by)
Form SCHEDULE 13G/A
01/27/2025
11:55 AM
Context Therapeutics (Subject)
FRANKLIN RESOURCES INC (Filed by)
Form SCHEDULE 13G
01/14/2025
7:36 PM
Context Therapeutics (Issuer)
Pasternak Andy (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/14/2025
7:43 PM
Context Therapeutics (Issuer)
Pasternak Andy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2025
4:03 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
6:37 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2025
3:07 PM
Context Therapeutics (Subject)
MPM BioImpact LLC (Filed by)
Form SCHEDULE 13G
12/23/2024
8:26 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/02/2024
3:20 PM
Context Therapeutics (Filer)
Form 424B5
12/02/2024
3:21 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
11:15 PM
Context Therapeutics (Filer)
Form EFFECT
11/14/2024
3:52 PM
Context Therapeutics (Subject)
GREAT POINT PARTNERS LLC (Filed by)
Form SC 13G/A
11/06/2024
4:08 PM
Context Therapeutics (Subject)
Hudson Bay Capital Management LP (Filed by)
Form SC 13G/A
11/06/2024
3:42 PM
Context Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
09/23/2024
6:33 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/17/2024
3:22 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2024
7:15 AM
Context Therapeutics (Issuer)
Smith Karen L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
7:01 AM
Context Therapeutics (Issuer)
Walker Luke Nathaniel (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/05/2024
7:04 AM
Context Therapeutics (Issuer)
Walker Luke Nathaniel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
7:08 AM
Context Therapeutics (Issuer)
Smith Karen L. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/04/2024
6:34 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
4:15 PM
Context Therapeutics (Issuer)
Dansky Ullmann Claudio (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
08/01/2024
4:18 PM
Context Therapeutics (Issuer)
Dansky Ullmann Claudio (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/24/2024
4:07 PM
Context Therapeutics (Filer)
Form DEFA14A
07/24/2024
3:55 PM
Context Therapeutics (Filer)
Form DEF 14A
07/10/2024
6:33 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/14/2024
6:52 AM
Context Therapeutics (Issuer)
Stacey Jennifer Evans (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:41 AM
BERMAN RICHARD J (Reporting)
Context Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:47 AM
Context Therapeutics (Issuer)
West Linda (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:50 AM
Context Therapeutics (Issuer)
Kantoff Philip W. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:34 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
9:45 AM
Context Therapeutics (Subject)
GREAT POINT PARTNERS LLC (Filed by)
Form SC 13G
06/02/2024
11:15 PM
Context Therapeutics (Filer)
Form EFFECT
05/24/2024
6:31 AM
Context Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
05/13/2024
9:37 AM
Avidity Partners Management LP (Filed by)
Context Therapeutics (Subject)
Form SC 13G
05/02/2024
6:37 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/26/2024
3:16 PM
Context Therapeutics (Filer)
Form ARS
04/26/2024
3:12 PM
Context Therapeutics (Filer)
Form DEFA14A
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad)

If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.

04/01/2024
6:32 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/22/2024
7:01 AM
Context Therapeutics (Issuer)
Lehr Martin A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/22/2024
7:01 AM
Context Therapeutics (Issuer)
Levit Alex C. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/22/2024
7:04 AM
Context Therapeutics (Issuer)
Minai-Azary Jennifer Lynn (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/21/2024
7:28 AM
Context Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/21/2024
6:36 AM
Context Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/21/2024
6:31 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
6:30 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:CNTX) was last updated on 3/4/2025 by MarketBeat.com Staff
From Our Partners